The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thu ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would become an oncology powerhouse with $8 billion blockbuster medications. Celgene share price surges 21% as Bristol-Myers Squibb (BMS) announces this acquisition. When the deal closes, Celgene shareholders would receive one BMS share, $50 in cash for each Celgene share, and one tradeable contingent value right for each share of Celgene. This contingent value right entitles its holder to gain a one-time potential payment of $9 in cash upon FDA approval of all 3 main medications of ozanimod (31 December 2020), liso-cel (31 December 2020) and bb2121 (31 March 2021).

BMS already owns a rich portfolio of blockbuster medications. These medications include the top-selling PD-1 checkpoint inhibitor Opdivo, the leukemia drug Sprycel, the melanoma drug Yervoy, the multiple-myeloma drugs Revlimid and Pomalyst, and the pancreatic cancer medicine Abraxane. These medications generate about $5.9 billion revenue in 2018Q3. These landmark medications position BMS as the market-share leader in immune-oncology and hematology.

The BMS specialty market niche and patent portfolio collectively create competitive moats for the new biopharma goliath in comparison to Johnson & Johnson, Merck, Pfizer, Roche, and Novartis etc.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth.

Daphne Basel

2020-10-27 07:43:00 Tuesday ET

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth.

Most agile lean enterprises often choose to cut costs strategically to make their respective business models fit for growth. Vinay Couto, John Plansky,

+See More

Public sentiment turns quite a bit against Facebook in light of the public issues around fake news.

Apple Boston

2017-12-03 08:37:00 Sunday ET

Public sentiment turns quite a bit against Facebook in light of the public issues around fake news.

Sean Parker, Napster founder and a former investor in Facebook, has become a "conscientious objector" on Facebook. Parker says Facebook explo

+See More

Thomas Piketty frames economic inequality as a global phenomenon.

Apple Boston

2017-01-11 11:38:00 Wednesday ET

Thomas Piketty frames economic inequality as a global phenomenon.

Thomas Piketty's recent new book *Capital in the Twenty-First Century* frames income and wealth inequality now as a global economic phenomenon. When

+See More

The U.S. Treasury yield curve inverts for the first time since the Global Financial Crisis.

Apple Boston

2019-04-09 11:29:00 Tuesday ET

The U.S. Treasury yield curve inverts for the first time since the Global Financial Crisis.

The U.S. Treasury yield curve inverts for the first time since the Global Financial Crisis. The key term spread between the 10-year and 3-month U.S. Treasur

+See More

The top Sino-U.S. tech titans now reach the trademark total market capitalization of $4 trillion as of July 2018.

Fiona Sydney

2018-07-07 10:33:00 Saturday ET

The top Sino-U.S. tech titans now reach the trademark total market capitalization of $4 trillion as of July 2018.

The east-west tech rivalry intensifies between BATs (Baidu, Alibaba, and Tencent) and FAANGs (Facebook, Apple, Amazon, Netflix, and Google). These Sino-U.S.

+See More

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI).

Chanel Holden

2018-07-19 18:38:00 Thursday ET

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI).

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI) to be a weighted-average of interest rates, exchange rat

+See More